METLIFE INC Form 425 September 05, 2008 Filed by Reinsurance Group of America, Incorporated

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed under other applicable sections

of the Securities Exchange Act of 1934

Subject Company: MetLife, Inc.

Commission File No.: 001-15787

Securities Act Registration File No.: 333-152828

On September 5, 2008, Reinsurance Group of America, Incorporated (RGA or the Company) made an electronic investor presentation available to investors in connection with the pending exchange offer by MetLife, Inc. (MetLife) to its stockholders of shares of class B common stock of RGA for common stock of MetLife.

Set forth below is a transcript of the oral presentation by A. Greig Woodring, President and Chief Executive Officer of RGA, and Jack B. Lay, Senior Executive Vice President and Chief Financial Officer of RGA, as well as the accompanying slide presentation (which is identical to the slides filed pursuant to Rule 425 on Friday, August 29, 2008). Information in the transcript is qualified in its entirety by reference to the accompanying slides and RGA s exchange offer prospectus dated August 11, 2008 (including the risk factors contained therein) and the documents incorporated by reference therein. Investors are urged to review the transcript and the slides, together with the exchange offer prospectus and incorporated documents, in their entirety.

Non-GAAP Financial Measures

In the transcript, RGA uses a non-GAAP financial measure called operating income as a basis for analyzing financial results. This measure also serves as a basis for establishing target levels and awards under RGA s management incentive programs. Management believes that operating income, on a pre-tax and after-tax basis, better measures the ongoing profitability and underlying trends of the company s continuing operations because that measure excludes the effect of net realized capital gains and losses, changes in the fair value of certain embedded derivatives and related deferred acquisition costs. These items tend to be highly variable primarily due to the credit market and interest rate environment and are not necessarily indicative of the performance of our underlying businesses. Additionally, operating income excludes any net gain or loss from discontinued operations, which management believes is not indicative of the company s ongoing operations. The definition of operating income can vary by company and is not considered a substitute for GAAP net income.

Additionally, the Company evaluates its stockholder equity position excluding the impact of Other Comprehensive Income, including with respect to return on equity (ROE) and book value per share, which are presented excluding accumulated other comprehensive income. This is also considered a non-GAAP measure. The Company believes it is important to evaluate its stockholders equity position to exclude the effect of Other Comprehensive Income since the net unrealized gains or losses included in Other Comprehensive Income primarily relate to changes in interest rates, credit spreads on its investment securities and foreign currency fluctuations that are not permanent and can fluctuate significantly from period to period.

Reconciliations of non-GAAP measures to the nearest GAAP measures are provided at the end of the accompanying slides under the caption Reconciliations of Non-GAAP Measures.

Cautionary Statement Regarding Forward-Looking Statements

This presentation contains both historical and forward-looking statements. Forward-looking statements are not based on historical facts, but rather reflect the Company s current expectations, estimates and projections concerning future results and events. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as anticipate, may, could, intend, intent, belief, estimate, plan, foresee, forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors that are difficult to predict and that may cause the Company s actual results, performance or achievements to vary materially from what is expressed in or indicated by such forward-looking statements. The Company cannot make any assurance that projected results or events will be achieved.

The risk factors set forth in the Company s prospectus dated August 11, 2008 and proxy statement/prospectus dated August 4, 2008 in the respective sections entitled Risk Factors, and the matters discussed in RGA s SEC filings, including the Management s Discussion and Analysis of Financial Condition and Results of Operations sections of RGA s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and RGA s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2008 and June 30, 2008, could affect future results, causing these results to differ materially from those expressed in RGA s forward-looking statements.

The forward-looking statements included in this document are only made as of the date of this document and RGA has no obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances.

Numerous important factors could cause actual results and events to differ materially from those expressed or implied by forward-looking statements including, without limitation, (1) adverse changes in mortality, morbidity, lapsation or claims experience, (2) changes in our financial strength and credit ratings or those of MetLife, Inc. ("MetLife"), the beneficial owner of a majority of our common shares, or its subsidiaries, and the effect of such changes on our future results of operations and financial condition, (3) inadequate risk analysis and underwriting, (4) general economic conditions or a prolonged economic downturn affecting the demand for insurance and reinsurance in our current and planned markets, (5) the availability and cost of collateral necessary for regulatory reserves and capital, (6) market or economic conditions that adversely affect our ability to make timely sales of investment securities, (7) risks inherent in our risk management and investment strategy, including changes in investment portfolio yields due to interest rate or credit quality changes, (8) fluctuations in U.S. or foreign currency exchange rates, interest rates, or securities and real estate markets, (9) adverse litigation or arbitration results, (10) the adequacy of reserves, resources and accurate information relating to settlements,

awards and terminated and discontinued lines of business, (11) the stability of and actions by governments and economies in the markets in which we operate, (12) competitive factors and competitors' responses to our initiatives, (13) the success of our clients, (14) successful execution of our entry into new markets, (15) successful development and introduction of new products and distribution opportunities, (16) our ability to successfully integrate and operate reinsurance business that we acquire, (17) regulatory action that may be taken by state Departments of Insurance with respect to us, MetLife, or its subsidiaries, (18) our dependence on third parties, including those insurance companies and reinsurers to which we cede some reinsurance, third-party investment managers and others, (19) the threat of natural disasters, catastrophes, terrorist attacks, epidemics or pandemics anywhere in the world where we or our clients do business, (20) changes in laws, regulations, and accounting standards applicable to us, our subsidiaries, or our business, (21) the effect of our status as an insurance holding company and regulatory restrictions on our ability to pay principal of and interest on our debt obligations, and (22) other risks and uncertainties described in this document and in our other filings with the Securities and Exchange Commission.

Additional Information

In connection with MetLife s proposed divestiture of most of its interest in RGA pursuant to a previously announced exchange offer, RGA has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 (No. 333-152828), as amended, that includes an exchange offer prospectus dated August 11, 2008, and MetLife has filed with the U.S. Securities and Exchange Commission a tender offer statement on Schedule TO that includes such exchange offer prospectus and related transmittal materials. The exchange offer prospectus and transmittal materials contain important information about the exchange offer and related matters, and have been mailed to MetLife s stockholders. This document is not an offer to sell the securities referenced in the exchange offer prospectus and it is not soliciting an offer to buy the securities referenced in the exchange offer prospectus in any state where the offer is not permitted. Such an offer may be made solely by a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The distribution of this communication may, in some countries be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions.

Investors and security holders are urged to read the exchange offer prospectus and any other related documents filed with the SEC, when they become available and before making any investment decision. None of MetLife, RGA or any of their respective directors or officers or the dealer managers appointed with respect to the exchange offer makes any recommendation as to whether you should participate in the exchange offer.

You will be able to obtain a free copy of the exchange offer prospectus and other related documents filed with the SEC by MetLife and RGA at the SEC s web site atwww.sec.gov. Free copies of RGA s filings also may be obtained by directing a request to RGA, Investor Relations, by phone to (636) 736-7243, in writing to Mr. John Hayden, Vice President-Investor Relations, Reinsurance Group of America, Incorporated, 1370 Timberlake Manor Parkway, Chesterfield, Missouri, 63017, or by email to investrelations@rgare.com. Free copies of MetLife s filings may be obtained by directing a request to MetLife, Investor Relations, by phone to (212) 578-2211, in

writing to MetLife, Inc., 1 MetLife Plaza, Long Island City, NY 11101, or by email to metlife.com. Those documents may also be obtained from D.F. King & Co., Inc., which has been retained by MetLife as the information agent for the transaction. To obtain copies of the exchange offer prospectus and related documentation, or if you have questions about the terms of the exchange offer or how to participate, you may contact the information agent at (212) 269-5550 (banks and brokers only) (collect) or (800) 825-0898 (toll free).

Transcript

The following is a transcript of the oral presentation by management of RGA that accompanies the slide presentation below, which should be reviewed in its entirety in conjunction with the transcript, including the Cautionary Statement regarding Forward-Looking Statements on slide 2, Non-GAAP Measures and Capital Allocation on slide 4, and the Reconciliation of Non-GAAP Measures on slides 44-47. Bracketed text are references to selected numbered slides.

Greig Woodring: [Slide 8] What we do at RGA is life reinsurance and our earnings therefore depend on mortality. That's good news, because mortality, although it's volatile and follows its own course, is not really correlated to other financial flows

and is highly predictable over longer periods of time.

In fact, RGA is the second largest North American life reinsurer, number one in terms of new business written. An important part of our business is facultative. We're the industry leaders in facultative business. These are the difficult cases to underwrite. They're high value-added services provided to the life insurance industry. There are no official statistics, but we feel very confident in claiming we're the largest, because nobody's really even that close to us.

We view that RGA has lots of opportunities. We've been growing at double-digit rates. We have a track record over a long period of time that generates consistent earnings throughout. Quarter-to-quarter you see volatility from mortality experience: who dies in the given quarter. But the track record is strong over time.

Our separation from MetLife will be a net benefit to RGA. We think that independence from MetLife will enhance the ability of RGA stock to take its own course. And we also have a leading management team in the industry.

[Slide 9] You can see the rankings in North America and worldwide. On a couple of different bases in North America, what we collect is life reinsurance and inforce in volume. So, you can see we have about \$1.4 trillion of life reinsurance inforce, second to Swiss Re. On a worldwide basis, what you see is premiums and RGA is the third largest, with about \$4.7 billion of gross life premium.

[Slide 10] If you take a look at our position in the marketplace that we serve, in North America, as I said, we've been the leading life reinsurer in new business in both the U.S. and Canada last year and the leader in the U.S. in the last couple of years. We are the largest facultative reinsurer by a fair margin.

This is a mature market. Its growth has subsided a bit. We're talking about high single digit growth, sort of like 7% to 8% at this point. And again, this is a market that we have operated in for a long time and the business on our books has generated consistent profit over that period of time.

Profits that we experienced in 2008 come from business written in all prior years. So, all of the past record is relevant here.

The most rapidly growing part of the world for life reinsurance as a growth industry is Asia. And in Asian markets we're the region-wide leader in new business, with about a 26% market share. That's according to NMG surveys that were done. We're the second largest reinsurer of new group business to Swiss Re and we're the market leader in terms of the number of new treaties entered into.

In Europe, we are probably a little bit underrepresented at this point. It provides opportunities for us to expand into Continental Europe in particular. We have established operations in the UK and Spain and everywhere else is fairly early on at this state. With all of the regulatory changes in Europe, there are a lot of opportunities in that market as well.

[Slide 11] You can see in this pie chart the breakdown of our business by geography and how it has evolved over time. The U.S. share of the pie is decreasing as a result of the growth in Asia and Europe.

[Slide 12] We mentioned our facultative business as an important feature. We have been recognized as the leader in this field for some time. We review over 100,000 facultative applications a year, averaging over \$1 million per policy. We place a sizeable proportion of these cases. In this part of the market the victories are one case at a time, so there are significant barriers to entry. It is difficult for other reinsurers to encroach upon our position here.

But in addition, it also provides a lot of extra leverage for us in the regular automatic business. In much of the regular automatic life reinsurance business we are able to leverage our facultative position into better shares or better prices.

[Slide 13] There are a lot of growth opportunities left in the life reinsurance business. In North America we are talking, as I said, about high single digit growth, sort of 8% growth. There are not a lot of new entrants into our business. The ones that have entered have not been very effective in making an impact. We also see a changeover into increasing amounts of annuities and

other types of products being written and reinsured. In addition, the stresses in the macro environment are creating a lot of opportunities for reinsurers, who provide a fast, flexible source of capital to companies as well in the life insurance space.

Internationally, Asia, as I said, is a place where life insurance is a growth industry and we're growing along with that. In many of these markets you're talking about high teens in terms of growth rates on an annual recurring basis.

Most of these markets, in particular some of the more developed ones like Japan and Korea, have very low penetration rates. And these have been our largest growth stories for the last several years, because we're not only seeing sizeable opportunities, but we're penetrating the market farther. And companies are reinsuring more than they have in the past.

Other markets, like China and India, are for really the intermediate future. It's not something that's going to make an impact in the near term.

[Slide 14] Here's a chart that shows the growth rate of the life reinsurance inforce in the United States and Canada. You can see in the United States it's slowed down considerably. In the last couple of years, it's been quite level. In fact, new business cession rates have been decreasing somewhat. But remember, our profits come from all the inforce in place and not just from new business. And so, it's really the inforce growth that's important here.

Canada's been growing a little bit faster, continued on high penetration rates and a lot of reasons structurally for companies in Canada to reinsure. Some of

those may change and you might see this fall back more towards the United States level.

[Slide 15] We went public in 1993 and you can see some selected compound growth rate numbers for RGA parameters here. All of them have increased substantially on a compound basis.

[Slide 16] We expect that the independence from MetLife will have a positive effect for RGA stock in particular. We will increase the float available in the marketplace and eliminate the overhang that's always been present when MetLife has owned more than 50% of the stock. They've been generally very good owners for RGA, but we are looking forward to independence and separation in this transaction.

[Slide 17] In the life reinsurance business the scarcest resource tends to be the people and the quality of experience that is warehoused within an organization and RGA has a lot of people that not only have deep experience, but long experience with RGA as well.

[Slide 18] Jack?

Jack Lay: [Slide 19] I'll start with the financial highlights. In terms of historical performance our operating EPS* over the last

five years has grown at a 14% rate. Premium, that is for the last year '07 over '06, grew at a 13% rate. And I'll talk a

little bit later about a five year compound annual growth rate.

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

ROE** was 14% last year. That's ex AOCI. Book value per share** growth has been 14% over the last five years or so.

And in terms of goals, we articulate an operating EPS* growth rate target of 14%. We're still comfortable with that number. And an ROE** percentage so to speak of 14%. That's our expectation over the intermediate term, which we typically define as the next two- to three-year period.

[Slide 20] Our next slide represents life reinsurance inforce. And you can see a 14% growth rate over that period of time. This is not a perfect metric in terms of determining the business vitality, but it's one of several that we monitor. And as you can see, we're over \$2 trillion, \$2.2 trillion at the end of the second quarter of 2008.

[Slide 21] Our premium growth rate, you see here a compound annual growth rate of 17% over the last four years. You can see about 14% growth rate, 2Q, year-to-date, 2Q '08 versus '07. We expect that to be in the 12 to 14% range for the year. So, that's obviously a little bit towards the high end of that range currently. That's an enterprise-wide growth rate.

[Slide 22] We reflect consolidated operating income* on this slide. You can see gross dollars on the left and on the right operating income per share.* Also on the right, you see in terms of per share a four-year growth rate of 14%. I commented on our expectations in terms of the intermediate term.

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

^{**}Excludes accumulated other comprehensive income. See Reconciliations of Non-GAAP Measures at the end of this presentation.

You see we're at \$2.82 for the first six months versus \$2.60 for the first six months of last year. We had a difficult first quarter in terms of mortality. We expect to have some mortality fluctuations and we did sustain that in the first quarter this year. Mortality was back on track in the second quarter. So, we're still at a point where, in terms of the guidance for the year, it remains to be seen. We have to follow on with a couple more strong quarters, but may still be in that guidance range that we articulated in January, which was \$6.00 to \$6.50 per share.

[Slide 23] This page reflects, over a five-year period, quarterly mortality volatility. And the takeaway here is even when we have difficult quarters and I described one earlier we're not like a P&C reinsurer, even a P&C primary company, where it can wipe out earnings if you do have a difficult quarter in terms of mortality expectations. It's merely a blip for us. And you can see relative, fairly consistent pattern here, that we don't have a lot of volatility, either up or down, as you can see.

[Slide 24] Book value per share***, you see an upward trend there. Five-year compound annual growth rate of 13% or \$45.00, ex AOCI at June 30th of 2008. And, as you can see from the slide, we add about a dollar or so per share each quarter, if we have a representative quarter.

[Slide 25] In terms of our capitalization, you can see equity versus debt and hybrids here. We feel we have a little bit of leveragability with respect to the rating agencies currently, several hundred million. Not a whole lot, but at

*** Book value excludes other comprehensive income. See Reconciliations of Non-GAAP Measures at the end of this presentation.

least some flexibility with respect to leverage associated with the current capitalization levels.

[Slide 26] Pie charts of our consolidated asset composition. At the end of last year, as well as at the end of the first six months, I would characterize our portfolio as relatively conservative. That is, compared to the typical life insurance company, ours probably is a little more conservative. Not a lot, but a little. It's an A quality, on average, portfolio, with the asset classes that you would normally see in an insurance company. And you can see the breakdown on this page reflecting pretty much the different types of asset classes.

You'll see one called funds withheld at interest. That represents asset portfolios that are on the books of some of our client companies. And because of the treaty structure, they maintain legal ownership of those securities, but the economics pass through to the reinsurer, in this case, RGA.

You can see a reference at the bottom, roughly 3% of our securities are below investment grade.

[Slide 27] With that, Greig, maybe you want to take the conclusion.

Greig Woodring:

[Slide 28] Yes, the last slide here I'll cover is pretty much a wrap up of a lot of things we've said before. We are the second largest North America reinsurer. And with a strong position in both the U.S. and Canadian markets, an extremely strong position in the facultative space within the North America markets and we use that to our advantage, not only as a business in its own right, but to increase the value of our other businesses.

We have multiple opportunities to grow because of the nature of our business and the nature of our operations around the world, in particular our strong position in Asia and our growing position in Continental Europe, we have a strong team in place that's delivered impressive results over a long period of time. And we believe that the separation from MetLife will be nothing but beneficial to RGA and RGA's stock price going forward.

The appendices to the slides below contain additional information regarding RGA s operating segments, an overview of the proposed transaction and reconciliations of non-GAAP measures.

Slide Presentation

Reinsurance Group of America

RGA / MET Exchange Offer September 2008

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

- This presentation contains both historical and forward-looking statements. Forward-looking statements are not based on historical facts, but rather reflect the
 - Company s current expectations, estimates and projections concerning future results and events. Forward-looking statements generally can be identified by
 - the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as believe, expect, anticipate, may,
 - could, intend, intent, belief, estimate, plan, foresee, likely, will or other similar words or phr forward-looking statements are not
- guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors that are difficult to predict and that
- may cause the Company s actual results, performance or achievements to vary materially from what is expressed in or indicated by such forward-looking
 - statements. The Company cannot make any assurance that projected results or events will be achieved.
- The risk factors set forth in the Company s prospectus dated August 11, 2008 and proxy statement/prospectus dated August 4, 2008 in the respective
- sections entitled Risk Factors, and the matters discussed in RGA's SEC filings, including the Management's Discussion and Analysis of Financial
 - Condition and Results of Operations sections of RGA s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and RGA s Quarterly
 - Reports on Form 10-Q for the fiscal quarters ended March 31, 2008 and June 30, 2008, could affect future results, causing these results to differ materially
 - from those expressed in RGA s forward-looking statements.
- The forward-looking statements included in this document are only made as of the date of this document and RGA has no obligation to publicly update any
 - forward-looking statement to reflect subsequent events or circumstances.
- Numerous important factors could cause actual results and events to differ materially from those expressed or implied by forward-looking statements
- including, without limitation, (1) adverse changes in mortality, morbidity, lapsation or claims experience, (2) changes in our financial strength and credit
 - ratings or those of MetLife, Inc. ("MetLife"), the beneficial owner of a majority of our common shares, or its subsidiaries, and the effect of such changes on
 - our future results of operations and financial condition, (3) inadequate risk analysis and underwriting, (4) general economic conditions or a prolonged
- economic downturn affecting the demand for insurance and reinsurance in our current and planned markets, (5) the availability and cost of collateral
- necessary for regulatory reserves and capital, (6) market or economic conditions that adversely affect our ability to make timely sales of investment
 - securities, (7) risks inherent in our risk management and investment strategy, including changes in investment portfolio yields due to interest rate or credit
- quality changes, (8) fluctuations in U.S. or foreign currency exchange rates, interest rates, or securities and real estate markets, (9) adverse litigation or
- arbitration results, (10) the adequacy of reserves, resources and accurate information relating to settlements, awards and terminated and discontinued lines
- of business, (11) the stability of and actions by governments and economies in the markets in which we operate, (12)

competitive factors and competitors'

- responses to our initiatives, (13) the success of our clients, (14) successful execution of our entry into new markets, (15) successful development and
- introduction of new products and distribution opportunities, (16) our ability to successfully integrate and operate reinsurance business that we acquire, (17)
- regulatory action that may be taken by state Departments of Insurance with respect to us, MetLife, or its subsidiaries, (18) our dependence on third parties,
 - including those insurance companies and reinsurers to which we cede some reinsurance, third-party investment managers and others, (19) the threat of
 - natural disasters, catastrophes, terrorist attacks, epidemics or pandemics anywhere in the world where we or our clients do business, (20) changes in laws,
- regulations, and accounting standards applicable to us, our subsidiaries, or our business, (21) the effect of our status as an insurance holding company and
- regulatory restrictions on our ability to pay principal of and interest on our debt obligations, and (22) other risks and uncertainties described in this document
 - and in our other filings with the Securities and Exchange Commission.

Additional Information and Where You Can Find It

- In connection with MetLife s proposed divestiture of its stake in RGA, on August 11, 2008, RGA filed with the Securities and Exchange Commission (the
- SEC) a registration statement on Form S-4 (No. 333-152828), as amended, which includes a form of prospectus relating to the exchange offer. On August
- 14, 2008, MetLife filed with the SEC a statement on Schedule TO. In addition, RGA has filed with the SEC a registration statement on Form S-4 (File No.
- 333-151390), as amended, which includes a final proxy statement/prospectus dated August 4, 2008 related to the recapitalization. **Investors and holders of**
- RGA and MetLife securities are strongly encouraged to read the registration statements and any other relevant documents filed with the SEC.
 - including the prospectus dated August 11, 2008 relating to the exchange offer and related exchange offer materials, the tender offer statement on
- Schedule TO, and the proxy statement/prospectus dated August 4, 2008 relating to the recapitalization, as well as any amendments and
 - supplements to those documents, because they contain important information about RGA, MetLife, and the proposed transactions. The
 - prospectus relating to the exchange offer and related exchange offer materials have been mailed to stockholders of MetLife. The proxy statement/prospectus
- relating to the recapitalization and related transactions has been mailed to shareholders of RGA. Investors and security holders can obtain free copies of the
 - registration statements, the prospectus relating to the exchange offer and related exchange offer materials and the tender offer statement on Schedule TO,
 - and the proxy statement/prospectus relating to the recapitalization, as well as other filed documents containing information about MetLife and RGA, without
- charge, at the SEC s web site (www.sec.gov). Free copies of RGA s filings also may be obtained by directing a request to RGA, Investor Relations, by phone
- to (636) 736-7243, in writing to Mr. John Hayden, Vice President-Investor Relations, Reinsurance Group of America, Incorporated, 1370 Timberlake Manor
 - Parkway, Chesterfield, Missouri, 63017, or by email to investrelations@rgare.com. Free copies of MetLife s filings may be obtained by directing a request to
 - MetLife, Investor Relations, by phone to (212) 578-2211, in writing to MetLife, Inc., 1 MetLife Plaza, Long Island City, NY 11101, or by email to
 - metir@metlife.com. Neither RGA, MetLife nor any of their respective directors or executive officers or the dealer managers, with respect to the exchange
 - offer makes any recommendation as to whether you should participate in the exchange offer.
- This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any
 - jurisdiction in which such solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Such an offer
 - may be made solely by a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. The distribution of this
 - communication may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform
 - themselves of and observe these restrictions.
 - RGA, MetLife and their respective directors and executive officers may be deemed, under SEC rules, to be participants in the solicitation of proxies from RGA s
- shareholders with respect to the proposed recapitalization. Information regarding the directors and executive officers

of RGA is included in its definitive proxy

statement for its 2008 Annual Meeting of Shareholders filed with the SEC on April 9, 2008. Information regarding the directors and officers of MetLife is

included in the definitive proxy statement for MetLife s 2008 Annual Meeting of Shareholders filed with the SEC on March 18, 2008. More detailed information

regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, is set forth in the proxy

statement/prospectus dated August 4, 2008 and the prospectus dated August 11, 2008 relating to the exchange offer, each as may be amended from time to

time, and other materials to be filed with the SEC in connection with the proposed transactions.

Participants in the Solicitation

Non-GAAP Measures

RGA uses a non-GAAP financial measure called operating income as a basis for analyzing financial results. This measure also serves as

a basis for establishing target levels and awards under RGA s management incentive programs. Management believes that operating

income, on a pre-tax and after-tax basis, better measures the ongoing profitability and underlying trends of the company s continuing

operations because that measure excludes the effect of net realized capital gains and losses, changes in the fair value of certain embedded

derivatives and related deferred acquisition costs. These items tend to be highly variable primarily due to the credit market and interest rate

environment and are not necessarily indicative of the performance of our underlying businesses. Additionally, operating income excludes

any net gain or loss from discontinued operations, which management believes is not indicative of the company s ongoing operations. The

definition of operating income can vary by company and is not considered a substitute for GAAP net income.

Additionally, the Company evaluates its stockholder equity position excluding the impact of Other Comprehensive Income . This is also

considered a non-GAAP measure. The Company believes it is important to evaluate its stockholders equity position to exclude the effect of

Other Comprehensive Income since the net unrealized gains or losses included in Other Comprehensive Income primarily relate to changes

in interest rates, credit spreads on its investment securities and foreign currency fluctuations that are not permanent and can fluctuate

significantly from period to period.

Reconciliations of non-GAAP measures to the nearest GAAP measures are provided at the end of this presentation.

Effective in 1Q 2006, the Company changed its capital allocation methodology from a regulatory-based approach to an economic-based

approach. To enhance comparability, all prior period segment results in this presentation have been adjusted to reflect the new methodology.

This change in capital allocation does not affect the Company s reported consolidated financial results.

Capital Allocation

Transaction Summary

Transaction Summary

Expiration of split-off may be extended to September 15, 2008, if exchange ratio limit is in effect at the end of the originally contemplated split-off period.

Recapitalization

RGA recapitalizes its single class of stock into two classes of stock (Class

A

low vote; Class B

high vote)

Results in 29,243,539 MET

-

owned shares of High Vote Class B Common

Stock

RGA Shareholder Vote

September 5, 2008

Shares

to Be

Exchanged (Split

-

Off)

29,243,539 RGA Class B Shares owned by MET

for

outstanding MET

Common Stock

Split

-

Off Fixed Discount

Mechanism

RGA Class B shares offered at a 10% discount to MET shareholders

subject to a limit of 1.3071 shares of RGA Class B

Common Stock per

share of MET

Split

Off Expiration

September 11, 2008

(1)

Potential

Conversion of

RGA Dual Class Stock

RGA currently expects that, following the transactions, the RGA

Board of

D

irectors

will consider submitting a proposal to RGA s sharehol

ders to

convert the dual

-

class structure into a single

-

class st

r

ucture. However,

there is no binding commitment by the RGA B

oard of

D

irectors

to

, and

there can be no assurance that the RGA Board of Directors will, consider

proposing a conversion or resolv

e to

submit such a proposal

to the RGA

shareholders

, and if submitted, there can be no

assurance

that the RGA

shareholders would approve

such a

conversion

Dealer Managers

Goldman Sachs

Merrill Lynch

Information Agent

D.F. King

Split

-

Off Website

http://www.dfking.com/metlife

RGA Investment Highlights

A. Greig Woodring (CEO)

RGA Investment Highlights

Second largest North American life reinsurer with established and expanding global presence

A leading facultative reinsurer with high degree of mortality expertise; provides competitive advantage

Multiple growth opportunities stemming from on-going industry consolidation and international expansion

Proven track record of delivering strong top and bottom-line growth

Increased independence post-separation from MetLife

Industry-leading management team

A Leading Life Reinsurer

Top Five Life Reinsurers Now Account for 76% of Market, Up From 48% in 1997

Source: 2007 Munich American / Society of Actuaries Reinsurance Survey

1.8

156.2

General Re Life

10

2.3

195.2

Canada Life

9

3.2

274.8

SCOR

8

4.3

362.4

Generali

7

4.8

406.4 ERC 6 9.9 850.0 Transamerica Re 5 11.4 970.0 Scottish Re 4 13.2 1,132.4 Munich American Re 3 **16.7** 1,429.1 **RGA** 2

24.5

\$2,090.8

Edgar Filing: METLIFE INC - Form 425

Edgar Filing: METLIFE INC - Form 425 Swiss Re 1 (\$ in billions) Share Market **Force Reinsurance In** Life Reinsurer Rank North America In 2007 Worldwide in 2006 Rank Reinsurer **Gross Life** Reinsurance **Premiums** (\$ in millions)

```
Swiss Re
$
10,378
2
Munich Re Group
```

10,114

RGA 4,732 4 Hannover Re 3,686 5 Scor 3,039 6 Berkshire Hathaway 2,476 7 Transamerica Re (Aegon) 2,259 8 Scottish Re Group, Ltd. 1,842 9 Reliastar 675 10 XL Re 597 Source: Standard & Poor's

Edgar Filing: METLIFE INC - Form 425

Operational Strength

Leading new business market share (23%) in $U.S.^{(1)}$

Leading new business market share (35%) in Canada⁽¹⁾

Largest facultative reinsurer⁽²⁾

High single-digit premium growth

Long track record of profitability

Region-wide leader in individual new business (26%)(3)

Second largest reinsurer of new group life (20%) market share⁽³⁾

Market leader in new treaty line acquisition⁽³⁾

Strong North American Market Positions

Third-largest life & health reinsurer in the $UK\&I^{(4)}$

Well-established in Spain

New Offices in Italy, Germany, France, and Poland

Changes in regulation and solvency measures expected to provide opportunities for new market entrants

Well Positioned in Rapidly Growing Asian Markets

Continued Expansion into Europe Offers Growth Opportunities

- (1) 2007 Munich American / Society of Actuaries Reinsurance Survey
 - (2) Based on Company estimate
 - (3) NMG Financial Services Consulting 2008 Programme (March)
- (4) NMG Financial Services Consulting Risk Premium Monitor 2006

Expanding Global Presence

Total 2003 Pre-tax Operating Income = \$263M

2003 Pre-tax Operating Income by Operating Segment

YTD June 30, 2008 Pre-tax Operating Income by Operating Segment

Note: Figures include results from the U.S., Canada, Asia Pacific and Europe & South Africa operating segments; exclude Corporate segment. See Reconciliations of Non-GAAP Measures at the end of this presentation.

Total YTD June 30, 2008 Pre-tax

Operating Income = \$289M

Leading Facultative Franchise

Recognized facultative expertise

Provide a market for non-conforming risks

Significant barriers to entry

Fosters closer relationships with cedants

Leverage for additional business opportunities

Provides some pricing power for automatic business

Frequent entry point for international business development

Significant Growth Opportunities

Expect intermediate growth of 8%-10% in traditional market going forward

Limited number of competitors; good pricing environment expected to continue

Little impact from startups

Some direct companies retaining more business

Highest growth rates likely to come from Asia Pacific (primarily Japan and South Korea)

Penetration rates in most of Asia Pacific are very low; Australia is the exception

UK growth is moderating; increase in number of competitors

India and China represent longer-term significant opportunities

EU solvency and other regulatory risk based capital initiatives will likely be a catalyst for additional reinsurance opportunities

North America

International

North America Market Continues to Grow

Source: Munich American / Society of Actuaries Reinsurance Surveys

(\$ in billions)
+8%
+15%
+5%
+4%
+2%
+76%
+12%
+16%
+1%
+16%
(\$ in billions)

Although cession rates in the U.S. market have fallen over the past several years, RGA has continued to grow through market share increases.

United States

Life Reinsurance Inforce

Life Reinsurance Inforce

Canada

Strong Track Record of Growth

Share Price	\$12.28*	\$52.48	10.9%
Market Cap	\$480M	\$3.3B	14.8%
Assets	\$1.2B	\$21.6B	22.9%
Net Income	\$34.1M	\$293.8M	16.6%
Premiums	\$380M	4.9B	20.0%
Employees	198	1,066	12.8%
	* Split-adjus	ted	
	December 3 1993	1,	
	December 3 2007	1,	
	CAGR		

Increased Independence Post-Separation from MetLife

Expected to eliminate overhang and increase liquidity and public float for RGA common stock

Expected to result in wider following by equity research community

Expected to facilitate use of RGA common stock as acquisition currency and source of capital and enhance the attractiveness of RGA s equity-based compensation plans

Expected to allow RGA to pursue future business initiatives free from constraint of a controlling corporate shareholder

Expected to eliminate potential customer conflicts, given that some key customers of RGA directly compete with MetLife

Expected to permit RGA shareholders to share in any premium associated with any subsequent change in control of RGA

For a broader discussion of the potential advantages and disadvantages of the separation from MetLife, see "RGA's Reasons for the Recapitalization" in the prospectus dated August 11, 2008

Industry-Leading Management Team

(1)

Includes experience in life insurance and life reinsurance industries

(2)

Includes experience with RGA s predecessor, the reinsurance division of General American Life Insurance Company

Years Experience

Name

Position

In Industry

(1)

With RGA

(2)

A. Greig Woodring

President, Chief Executive Officer, and Director

33

29

Jack B. Lay

Senior E.V.P. and Chief Financial Officer

17

14

Paul A. Schuster

Senior E.V.P., U.S. Operations

32

17

Graham S. Watson

Senior E.V.P., International and Chief Marketing Officer

38

12

David B. Atkinson

E.V.P.

33

22

Brendan J. Galligan

E.V.P., Asia Pacific

30

18

John P. Laughlin

E.V.P., U.S. Financial Markets

24

13

Robert M. Musen

E.V.P.

32

8

Paul Nitsou

E.V.P., International

23

12

Alain P. Neemeh

President and Chief Executive Officer, RGA Canada

Edgar Filing: METLIFE INC - Form 425 11 11 A. David Pelletier E.V.P. 24 13 Michael S. Stein E.V.P., U.S. Operations

Overview of Financial Performance

Jack B. Lay (CFO)

Financial Highlights

Operating EPS Growth 14% (5-year CAGR, 2003-2007)

Premium Growth 13% (2007 compared to 2006)

Return on Equity* 14% (2007)

BV/Share Growth* 14% (5-year and 14-year CAGR)

Operating EPS Growth 14%

Return on Equity* 14%

Historical Performance

Intermediate Goals

RGA targets debt leverage of 25% or less, commensurate with various rating agency guidelines for existing ratings.

* Excludes accumulated other comprehensive income. See Reconciliations of Non-GAAP Measures at the end of this presentation.

Life Reinsurance In Force

(\$ in billions)

Consolidated Net Premiums

(\$ in millions)

Consolidated Operating Income

Operating Return on Equity⁽¹⁾

2003 13%

2004 12%

2005 11%

2006 13%

2007 14%

Operating Income

(\$ in millions)

Operating Income Per Share

(1)

Operating ROE is computed excluding accumulated other comprehensive income, using quarterly average for equity amounts. See Reconciliations of Non-GAAP Measures at the end of this presentation.

Quarterly Mortality Volatility

5 Year Average = 81.4%

RGA s results can exhibit quarterly volatility in mortality experience, but when measured over longer periods of time, mortality experience is more predictable and stable.

Book Value Per Share* 5 Year Trend

^{*} Book value excludes other comprehensive income. See Reconciliations of Non-GAAP Measures at the end of this presentation.

Total Capitalization Levels (Excluding Other Comprehensive Income)*

(\$ in millions)

Debt & Hybrids/

Total Capitalization 24.4% 26.6%	22.5% 28.9%	31.5% 27.9%
	\$2,279	
	\$2,505	
	\$3,039	
	\$3,246	
	\$3,748	
	\$3,891	

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

Consolidated Asset Composition

(\$ in millions)	Carrying Value	Carrying Value	YTD
Asset Type	Dec. 31, 2007	June 30, 2008	
	<u>Change</u>	-	
Fixed Maturities	\$ 9,398	\$ 9,668	\$ 270
Mortgage Loans	832	799	(33)
Policy Loans	1,059	1,048	(11)
Funds Withheld at Interest	4,749	4,825	76
Cash and Short Term	47	70	
41		(69)	
Other	284	419	
	135		
	\$ 16, \$ 368	801 \$ 17,	169

Well-diversified fixed maturity portfolio; 97% investment grade as of June 30, 2008

Conclusion

A. Greig Woodring (CEO)

RGA Investment Highlights

Second largest North American life reinsurer with established and expanding global presence

A leading facultative reinsurer with high degree of mortality expertise; provides competitive advantage

Multiple growth opportunities stemming from ongoing industry consolidation and international expansion

Proven track record of delivering strong top and bottom-line growth

Increased independence post-separation from MetLife

Industry-leading management team

Appendix:

RGA s Operating Segments

Transaction Diagram

Reconciliations of Non-GAAP Measures

RGA s Operating Segments

U.S. Operations

Total U.S. Operations

Pre-tax Operating Income*

(\$ in millions)

Net Premiums

(\$ in millions)

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

U.S. Traditional Operations

RGA s goal is to be among those 3-5 with very favorable terms

Automatic reinsurance programs are placed with 3-5 reinsurers

RGA s differentiator is our facultative services

Companies cannot access these services unless RGA is participating automatically in their reinsurance

In order to maintain our industry-leading facultative position, we focus on continually refining and improving these services

Competitive offers

Industry-leading time service

Solid, individual life capacity

Facultative Application Console (FAC)

AURA technologybased rules engine (ASAP)

Underwriting Connection

Yearly seminars, newsletters

Approach to the Market

Facultative Excellence

\$1.3 trillion of life reinsurance inforce

Largest source of revenue and earnings

Quality, long-term, client base

Recognized leader in facultative underwriting; over 100,000 applications in 2007

Adverse claim levels in 1Q 2008

Overview

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

U.S. Asset Intensive and Financial Reinsurance Sub-segments

Primarily annuities and COLI/BOLI; a spread business

Some volatility in operating income due to treatment of realized gains/losses for funds withheld treaties

RGA shares in asset risk for general account annuity transactions

Opportunistic growth; provides meaningful diversification from mortality risk

Pre-tax Operating Income*

(\$ in millions)

Asset Intensive

Financial Reinsurance

A recognized leader in this highly specialized market

Limited new opportunities currently in U.S.; stronger opportunities in Asia Pacific

Intellectual capital is essential due to complexity of transactions

Generally a fee-based business for RGA; rely on retrocession capacity

Pre-tax Operating Income*

(\$ in millions)

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

Canada Operations

Canada Operations

Established in 1992

Traditional individual life reinsurance, including preferred classes; some creditor business

Most of the life insurance companies in Canada are clients

A market leader; primary competitors are Munich Re and Swiss Re

Strong results and favorable mortality in 2007 and first half of 2008

Overview

Premiums

\$ in millions

Pre-tax Operating Income*

\$ in millions

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

International Operations

International Operations Overview

Have demonstrated success

Built green-field operations across the globe; centrally managed by dedicated team in Toronto

Developed divisional infrastructure and culture

Established as a leading reinsurer in key markets

Focused on multi-nationals and larger local companies

Reinsurance products include life and critical illness

Europe & South Africa Operations

Spain 1995

England 1999

South Africa 1999

India 2002

Ireland 2003

Poland 2006

Germany 2006

France 2007

Italy 2007

UK market has fueled past growth; 12%-15% premium growth expected going forward

Increasing continental Europe presence

Offices recently established in France, Germany, Italy and Poland

Reinsurance products include life YRT and coinsurance, accelerated critical illness

India viewed as providing long-term growth opportunities

Adverse claim levels in UK and South Africa in Q1 2008

Overview

Markets and Date of Entry

Net Premiums

Pre-tax Operating Income*

\$ in millions

\$ in millions

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

Asia Pacific Operations

Hong Kong 1994

Japan 1995

Australia/New Zealand 1996

Malaysia 1997

Taiwan 1999

South Korea 2002

China 2005

Overview

Markets and Date of Entry

Net Premiums

Pre-tax Operating Income*

\$ in millions

\$ in millions

Strong results in 2006, 2007 and first half of 2008 lead by Australia, Japan and South Korea

A recognized leader in the Asia Pacific region based on NMG survey

Japan and South Korea should lead growth in near term

Strong facultative market in Japan

Opened office in China in 2005; longer-term growth opportunity

^{*} See Reconciliations of Non-GAAP Measures at the end of this presentation.

Transaction Diagram

Transaction Diagram

Status Quo

Step 1: Recapitalization of RGA Stock

RGA recapitalizes its single class of stock into two classes of stock (Class A low vote;

Class B high vote)

MET exchanges substantially all of its stake for all Class B shares⁽¹⁾

RGA Class A Shares (<20% Vote)

RGA Class A & B Shares⁽¹⁾⁽²⁾ (>80% Vote)

(1) In addition to the Class B shares, MET will also own 3 million Class A shares which it will dispose of within 60

months of the completion of the split-off.

Class B shares carry high vote, having the right to elect at least 80% of the board of directors.

RGA

Other MET Businesses

MET

Existing MET

Shareholders

48%

Vote

52%

Vote

Existing RGA

Shareholders

RGA

Other MET Businesses

MET

Existing MET

Shareholders

Existing RGA

Shareholders

Transaction Diagram (Cont d)

Step 2: Split-Off (Exchange Offer)

RGA

Other MET Businesses

MET

Existing MET

Shareholders

Existing RGA

Shareholders

MET splits-off all of its RGA Class B shares in exchange for MET shares

RGA Class B shares offered at a 10% discount subject to a limit of 1.3071 shares of RGA Class B Common Stock per share of MET

RGA

Class A

Shares

RGA

Class B

Shares

MET

Shares

RGA

Class A

Shares

Reconciliations of Non-GAAP Measures

Financial Performance

(1) Net of DAC offset
14.8
11.1
23.4
24.6
16.8
21.0
7.7
Pre-tax Operating Income
47.5
0.9
37.5
(2.8)
(0.5)
2.0
(12.9)
Change in MV of Embedded Derivatives(1)
(1.5)
1.6
8.2
7.2
1.0
7.3

1.4

Realized Capital (Gains) / Losses (1)

(31.2)

8.6

(22.3)

20.2

16.3

11.7

19.2

GAAP Pre-Tax Income - Cont Ops

YTD 2Q08

YTD 2Q07

2007

2006

2005

2004

2003

U.S. ASSET-INTENSIVE

153.2

170.0

351.4

291.2

241.0

251.2

195.7

Pre-tax Operating Income

Edgar Filing: METLIFE INC - Form 425
4.9
13.8
4.1
8.6
(18.1)
6.6
Realized Capital (Gains) / Losses
150.1
165.1
337.6
287.1
232.4
269.3
189.1
GAAP Pre-Tax Income - Cont Ops
YTD 2Q08
YTD 2Q07
2007
2006
2005
2004
2003
U.S. TRADITIONAL OPERATIONS
(10.0)
(22.8)
(29.6)

Edgar Filing: METLIFE INC - Form 425 (37.6)(41.8)(9.0)(9.3) **Pre-tax Operating Income** 0.1 11.8 12.5 (4.0)(17.4)(7.8)(0.9)Realized Capital (Gains) / Losses (10.1) (34.6)(42.1)(33.6)(24.4) (1.2)(8.4)**GAAP Pre-Tax Income - Cont Ops YTD 2Q08 YTD 2Q07** 2007 2006 2005

Edgar Filing: METLIFE INC - Form 425
2004
2003
CORPORATE & OTHER SEGMENT
40.8
26.5
61.6
59.0
31.5
7.1
13.3
Pre-tax Operating Income
1.0
0.6
1.5
0.4
0.3
(0.3)
0.1
Realized Capital (Gains) / Losses
39.8
25.9
60.1
58.6
31.2
7.4

GAAP Pre-Tax Income - Cont Ops

YTD 2Q08

YTD 2Q07

2007

2006

2005

2004

2003

ASIA-PACIFIC OPERATIONS

(\$ in millions)

Reconciliation of Pre-Tax Income to Pre-Tax Operating Income

22.5

33.8

49.7

58.6

35.8

27.3

15.2

Pre-tax Operating Income

(0.6)

0.8

2.2

0.3

0.3

(2.3)

(2.6)

Realized Capital (Gains) / Losses

23.1

33.0

47.5

58.3

35.5

29.6

17.8

GAAP Pre-Tax Income - Cont Ops

YTD 2Q08

YTD 2Q07

2007

2006

2005

2004

2003

EUROPE & SOUTH AFRICA OPERATIONS

51.9

35.1

74.9

40.6

46.8

31.2

18.2

Pre-tax Operating Income

Edgar Filing: METLIFE INC - Form 425
(4.1)
(6.6)
(5.2)
(3.4)
(8.1)
(9.9)
Realized Capital (Gains) / Losses
50.4
39.2
81.5
45.8
50.2
39.3
28.1
GAAP Pre-Tax Income - Cont Ops
YTD 2Q08
YTD 2Q07
2007
2006
2005
2004
2003
CANADA OPERATIONS
U.S. FINANCIAL REINSURANCE
2003

_

Pre-tax Operating Income

12.6

13.1

15.1

15.0

12.6

5.7

5.6

TOTAL US OPERATIONS SEGMENT

2003

2004

2005

2006

2007

YTD 2Q07

YTD 2Q08

GAAP Pre-Tax Income - Cont Ops

220.9

294.1

263.8

322.3

327.9

179.4

Realized Capital (Gains) / Losses(1)

8.0

(10.8)

9.6

11.3

22.0

6.5

1.6

Change in MV of Embedded Derivatives(1)

(12.9)

2.0

(0.5)

(2.8)

37.5

0.9

47.5

Pre-tax Operating Income

216.0

285.3

272.9

330.8

387.4

186.8

173.6

(1) Net of DAC offset

Financial Performance

(1) Net of DAC offset
278.8
259.4
544.0
451.4
345.2
341.9
253.4
Pre-tax Operating Income
47.5
0.9
46.5
(2.8)
(0.5)
2.0
(12.9)
Change in MV of Embedded Derivatives(1)
3.6
15.6
22.6
2.8
(10.6)
(29.3)

(5.3)

Realized Capital (Gains) / Losses(1)

227.7

242.9

474.9

451.4

356.3

369.2

271.6

GAAP Pre-Tax Income - Cont Ops

YTD 2Q08

YTD 2Q07

2007

2006

2005

2004

2003

RGA CONSOLIDATED

\$

2.82

\$

2.60

\$


5.50

\$

4.65

\$

3.54	
\$	
3.57	
\$	
3.22	
Operating EPS from Co	ont. Operations
0.08	
0.04	
0.22	
0.08	
0.10	
0.18	
0.37	
0.37	
0.11	
Loss from Discontinue	ed Operations
	- O Personolis
0.48	
0.01	



Edgar Filing: METLIFE INC - Form 425 2.22 \$ 2.39 \$ 4.57 \$ 4.57 \$ 3.52 \$ 3.52 \$ 3.36 **GAAP Net Income YTD 2Q08 YTD 2Q07** 2007

2006

2005

2004

2003

Per Diluted Share Basis

CONSOLIDATED EPS RECONCILIATION

Stockholders Equity Reconciliation

Consolidated EPS Reconciliation

(\$ in millions)

Reconciliation of Pre-Tax Income to Pre-Tax Operating Income

2003
2004
2005
2006
2007
YTD 2Q07
YTD 2Q08
GAAP Stockholders' Equity
1,947.7
\$
2,279.0
\$
2,527.5
\$

\$

3,189.8

2,815.4

\$

2,894.6

\$

3,061.4

\$

FAS 115 Equity Adjustment

Edgar Filing: METLIFE INC - Form 425 244.7 361.8 335.6 313.2 204.1 47.5 Foreign Currency Adjustment 53.6 93.7 85.1 109.1 222.0 182.0 215.6 **Unrealized Pension** 0.0 0.0 0.0 (11.3) (8.4)(11.6)(8.1) Equity Excluding OCI 1,723.5 \$

1,940.6

Edgar Filing: METLIFE INC - Form 425 \$ 2,080.6 \$ 2,382.0 \$ 2,663.0 \$ 2,520.1 \$ 2,806.4 \$ GAAP Stockholders' Average Equity 1,460.8 \$ 2,071.7 \$ 2,423.4 \$ 2,613.8 \$ 2,965.8 \$ 2,866.4

\$

\$

3,103.4

nent

Edgar Filing: METLIFE INC - Forr
FAS 115 Average Equity Adjustm
148.5
180.0
310.5
310.3
287.9
282.2
293.3
175.9
Foreign Currency Adjustment
26.9
54.6
34.0
84.1

102.3

174.9

91

138.0

213.7

Unrealized Pension

-

_

-

(2.3)

(10.9)

(11.4)

(8.2)

Average Equity Excluding OCI

1,285.4

\$

1,837.0

\$

2,028.8

\$

Edgar Filing: METLIFE INC - Form 425 2,225.8 \$ 2,519.6 \$ 2,446.5 \$ 2,721.9 \$ Operating ROE - GAAP Stockholders' Equity 11% 11% 9% 11% 12% 6% 6% Operating ROE - Excluding OCI 13% 12% 11% 13% 14% 7% 7%

Financial Performance

Pre-Tax Operating Earnings YTD

(\$ in millions)

Book Value per Share Reconciliation

2Q08

1Q08

4Q07

3Q07

2Q07

1Q07

4Q06

3Q06

2Q06

1Q06

4Q05

Book value per share

49.13

\$

49.15

\$

51.42

\$

49.03

\$

Edgar Filing: METLIFE INC - Form 425 \$ 46.81 \$ 45.85 \$ 45.22 \$ 40.30 \$ 40.62 \$ 41.38 \$ Less: effect of FAS 115 0.76 2.69 5.04 3.52 3.29

Edgar Filing: METLIFE INC - Form 425
5.46
5.02
5.93
2.14
4.04
5.92
Less: effect of CTA
3.46
3.27
3.58
3.84
2.94
1.99
1.70
1.78

1.92
1.36
1.40
Less: effect of Pension Benefit
(0.13)
(0.13)
(0.13)
(0.19)
(0.19)
(0.18)
(0.18)
-

-

-

Book value per share excluding OCI

45.04

\$

43.32

\$

42.93

\$

41.86

\$

40.65

\$

39.49

\$

38.79

\$

37.39

\$

36.24

\$

35.22

\$

Edgar Filing: METLIFE INC - Form 425 \$ 3Q05 2Q05 1Q05 4Q04 3Q04 2Q04 1Q04 4Q03 3Q03 2Q03 1Q03 Book value per share 40.33 \$ 39.60 \$

36.79

\$

36.50

\$

33.92

\$

31.38

\$

\$ 31.33 \$ 28.92 \$ 28.93 \$ 25.18 \$ Less: effect of FAS 115 5.52 6.22 3.37 3.92 2.91 1.21 3.67

2.74

Edgar Filing: METLIFE INC - Form 425

Edgar Filing: METLIFE INC - Form 425 3.47 4.19 1.76 Less: effect of CTA 1.45 1.04 1.36 1.50 0.75 0.49 0.77 0.86

0.67

0.21

Less: effect of Pension Benefit

-

_

_

_

-

_

_

_

-

-

_

Book value per share excluding OCI

33.36

\$

32.34

\$

32.06

\$

31.08

\$

30.26

\$

29.68

\$

28.67

\$

27.73

\$

24.78

\$

24.01

\$

23.21

\$

Reinsurance Group of America

RGA / MET Exchange Offer September 2008